A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes
A Randomized, Open-Label, Parallel-Group, Single-dose, Biocomparability Study of the Pharmacokinetics of the Abatacept (BMS-188667) Drug Product Converted From Drug Substance of a New Abatacept Drug Substance Process Relative to the Current Abatacept Drug Process in Healthy Participants
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
South Miami, Florida, United States, 33143
- Qps-Mra, Llc
-
-
Texas
-
Austin, Texas, United States, 78744
- PPD Development, LP
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Body weight will be between 60 and 100 kg, inclusive.
- Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 24 hours prior to the start of study treatment.
- Women must not be breastfeeding.
- WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with abatacept plus 5 half-lives of abatacept (85 days) plus 30 days (duration of ovulatory cycle) for a total of 115 days post-treatment completion.
- Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with abatacept plus 5 half-lives of abatacept (85 days) plus the duration of spermatogenesis (90 days) for a total of 175 days after the last dose of study treatment. In addition, male participants must be willing to refrain from sperm donation during this time.
Exclusion Criteria:
- Participants who have a present malignancy or previous malignancy within the last 5 years prior to screening (except documented history of cured non-metastatic squamous or basal cell skin carcinoma or cervical carcinoma in situ). Participants who had a screening procedure that is suspicious for malignancy, and in whom the possibility of malignancy cannot be reasonably excluded following additional clinical, laboratory or other diagnostic evaluations.
- Participants with a history of herpes zoster.
- Donation of blood to a blood bank or in a clinical study (except a screening visit or follow-up visit) within 4 weeks of study treatment administration (within 2 weeks of study treatment administration for plasma only).
- Blood transfusion within 4 weeks of study treatment administration.
- Recent (within 6 months of study treatment administration) history of smoking or current smokers. This includes participants using electronic cigarettes or nicotine-containing products such as tobacco for chewing, nicotine patches, nicotine lozenges, or nicotine gum.
- History of allergy to abatacept or related compounds.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Treatment A
Participants will receive abatacept at a single dose of 750 mg as IV infusion on Day 1 converted from drug substance by a new process.
|
Participants will receive abatacept at a single dose 750 mg as IV infusion.
|
|
ACTIVE_COMPARATOR: Treatment B
Participants will receive abatacept at a single dose 750 mg as IV infusion on Day 1 converted from drug substance by converted from drug substance by the current process.
|
Participants will receive abatacept at a single dose 750 mg as IV infusion.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximum Observed Serum Concentration (Cmax)
Time Frame: From drug administration to 70 days following drug administration
|
Maximum Observed Serum Concentration
|
From drug administration to 70 days following drug administration
|
|
Area Under the Curve AUC(INF)
Time Frame: From drug administration to 70 days following drug administration
|
Area under the serum concentration-time curve from time zero extrapolated to infinity
|
From drug administration to 70 days following drug administration
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time of Maximum Observed Serum Concentration (Tmax)
Time Frame: From drug administration to 70 days following drug administration
|
Time of maximum observed serum concentration
|
From drug administration to 70 days following drug administration
|
|
Area Under the Curve AUC(0-T)
Time Frame: From drug administration to 70 days following drug administration
|
Area under the serum concentration-time curve from zero to the last time of the last quantifiable concentration
|
From drug administration to 70 days following drug administration
|
|
Area Under the Curve AUC(0-28)
Time Frame: From drug administration to 70 days following drug administration
|
Area under the serum concentration-time curve from time zero to 28 days after dosing
|
From drug administration to 70 days following drug administration
|
|
Total Body Clearance (CLT)
Time Frame: From drug administration to 70 days following drug administration
|
Total body clearance
|
From drug administration to 70 days following drug administration
|
|
Volume of Distribution at Steady-State (Vss)
Time Frame: From drug administration to 70 days following drug administration
|
Volume of distribution at steady-state
|
From drug administration to 70 days following drug administration
|
|
Terminal Phase Elimination Half-life (T-HALF)
Time Frame: From drug administration to 70 days following drug administration
|
Terminal phase elimination half-life in serum
|
From drug administration to 70 days following drug administration
|
|
Number of Participants Experiencing Positive Immunogenicity Response to Abatacept
Time Frame: From Day 1 (Predose) to Day 71 (Study Discharge), assessed at day 1, day 29, day 57 and day 71
|
Positive immunogenicity response to Abatacept was defined if one of the following criteria was met:
|
From Day 1 (Predose) to Day 71 (Study Discharge), assessed at day 1, day 29, day 57 and day 71
|
|
Number of Participants Experiencing Adverse Events
Time Frame: From drug administration to 56 days following drug administration
|
Number of participants experiencing different types of Adverse Events (AEs).
Peri-infusional AEs: occurring during the 30 minute study drug infusion period Post-infusional AEs: occurring within 24 hours post drug infusion
|
From drug administration to 56 days following drug administration
|
|
Change From Baseline in Blood Pressure
Time Frame: From baseline (last result before start of study medication) to 70 days after start of study medication
|
Mean Change from Baseline in systolic and diastolic blood pressure values
|
From baseline (last result before start of study medication) to 70 days after start of study medication
|
|
Change From Baseline in Heart Rate
Time Frame: From baseline (last result before start of study medication) to 70 days after start of study medication
|
Mean Change from Baseline in heart rate values
|
From baseline (last result before start of study medication) to 70 days after start of study medication
|
|
Change From Baseline in Respiration Rate
Time Frame: From baseline (last result before start of study medication) to 70 days after start of study medication
|
Mean Change from Baseline in respiration rate values
|
From baseline (last result before start of study medication) to 70 days after start of study medication
|
|
Change From Baseline in Body Temperature
Time Frame: From baseline (last result before start of study medication) to 70 days after start of study medication
|
Mean Change from Baseline in body temperature values
|
From baseline (last result before start of study medication) to 70 days after start of study medication
|
|
Change From Baseline in Electrocardiogram (ECG) Parameters
Time Frame: From baseline (last result before start of study medication) to 70 days after start of study medication
|
Mean Change from Baseline in ECG parameters, including PR interval, QRS interval, QT interval, and QTC Fridericia
|
From baseline (last result before start of study medication) to 70 days after start of study medication
|
|
Number of Participants Experiencing Clinically Significant Physical Examination Abnormalities
Time Frame: From the pre-treatment period to 70 days after start of study medication (approximately 100 days)
|
Number of participants experiencing clinically significant physical examination abnormal findings
|
From the pre-treatment period to 70 days after start of study medication (approximately 100 days)
|
|
Change From Baseline in Laboratory Test Results - Hematology 1
Time Frame: From baseline (last result before start of study medication) to 70 days after start of study medication
|
Mean Change from Baseline in laboratory test results - Hematology parameters 1
|
From baseline (last result before start of study medication) to 70 days after start of study medication
|
|
Change From Baseline in Laboratory Test Results - Hematology 2
Time Frame: From baseline (last result before start of study medication) to 70 days after start of study medication
|
Mean Change from Baseline in laboratory test results - Hematology parameters 2
|
From baseline (last result before start of study medication) to 70 days after start of study medication
|
|
Change From Baseline in Laboratory Test Results - Hematology 3
Time Frame: From baseline (last result before start of study medication) to 70 days after start of study medication
|
Mean Change from Baseline in laboratory test results - Hematocrit
|
From baseline (last result before start of study medication) to 70 days after start of study medication
|
|
Change From Baseline in Laboratory Test Results - Chemistry 1
Time Frame: From baseline (last result before start of study medication) to 70 days after start of study medication
|
Mean Change from Baseline in laboratory test results - Chemistry parameters 1
|
From baseline (last result before start of study medication) to 70 days after start of study medication
|
|
Change From Baseline in Laboratory Test Results - Chemistry 2
Time Frame: From baseline (last result before start of study medication) to 70 days after start of study medication
|
Mean Change from Baseline in laboratory test results - Chemistry parameters 2
|
From baseline (last result before start of study medication) to 70 days after start of study medication
|
|
Change From Baseline in Laboratory Test Results - Chemistry 3
Time Frame: From baseline (last result before start of study medication) to 70 days after start of study medication
|
Mean Change from Baseline in laboratory test results - Chemistry parameters 3
|
From baseline (last result before start of study medication) to 70 days after start of study medication
|
|
Change From Baseline in Laboratory Test Results -Hematology and Chemistry 4
Time Frame: From baseline (last result before start of study medication) to 70 days after start of study medication
|
Mean Change from Baseline in laboratory test results - hematology and chemistry parameters 4
|
From baseline (last result before start of study medication) to 70 days after start of study medication
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Arthritis, Rheumatoid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Immune Checkpoint Inhibitors
- Abatacept
Other Study ID Numbers
Other Study ID Numbers
- IM101-682
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.